SUNPHARMA
OVERVALUEDSun Pharmaceutical
Pharma · NSE
↓ 121.1% vs fair value
52W Low
₹1,548
+9.8% from low
52W High
₹1,851
-8.2% from high
Valuation Gauge
Current Price
₹1,699
Fair Value
₹768
Fair Value Analysis
₹768
Based on free cash flow projections and earnings growth potential for Pharma sector companies | ROCE improving (latest 20.3%) — capital allocation becoming more efficient.
Cash Flow Analysis
38% weight
Growth Valuation
63% weight
Price vs Market
Shareholding Pattern
Stock Health Score
Financially Strong
Profitability
ROE of 14.1% is acceptable for Pharma sector (benchmark: 18%)
Debt & Leverage
D/E ratio of 0.1x is well within the Pharma sector norm of 0.8x — strong balance sheet
Valuation vs Peers
P/E of 37.2x is slightly below the Pharma sector median of 42x — reasonably valued
Cash Flow
FCF margin of 23.0% — exceptional cash generation (₹11,944 Cr)
Earnings Growth
5yr EPS CAGR of 49.5% is well above the Pharma sector average of 15.3% — strong growth
Dividend
Dividend yield of 1.0% provides moderate shareholder returns
Sentiment Trend — Last 30 Days
Historical Returns
Key Ratios & Growth
FCF Yield
2.2%
Free cash flow / market cap
Revenue Growth (YoY)
+13.5%
Year-on-year revenue change
Profit Growth (YoY)
+16.1%
Year-on-year PAT change
Operating Cash Flow
₹14.1K Cr
TTM cash from operations
Key Financials
EPS (TTM)
₹45.5
P/E Ratio
37.2x
P/B Ratio
5.2x
ROE
14.1%
ROCE
18.9%
Debt / Equity
0.07x
Beta
0.11
Div Yield
1%
FCF (Cr)
₹11,944 Cr
Revenue (Cr)
₹52,041 Cr
EPS Growth 5Y
49.5%
Mkt Cap (Cr)
₹4,06,351 Cr
52W High
₹1,851.2
52W Low
₹1,548
Book Value/Share
₹323.2
Financial History
| Period | Revenue | Op Profit | OPM% | PAT | EPS |
|---|---|---|---|---|---|
| TTM | ₹56.8K Cr | ₹17.5K Cr | 31.0% | ₹11.0K Cr | ₹45.50 |
| 2025-03-31 | ₹52.6K Cr | ₹15.1K Cr | 29.0% | ₹11.0K Cr | ₹45.55 |
| 2024-03-31 | ₹48.5K Cr | ₹13.0K Cr | 27.0% | ₹9.6K Cr | ₹39.91 |
| 2023-03-31 | ₹43.9K Cr | ₹11.7K Cr | 27.0% | ₹8.5K Cr | ₹35.32 |
| 2022-03-31 | ₹38.7K Cr | ₹10.3K Cr | 27.0% | ₹3.4K Cr | ₹13.64 |
| 2021-03-31 | ₹33.5K Cr | ₹8.5K Cr | 25.0% | ₹2.3K Cr | ₹12.10 |
| 2020-03-31 | ₹32.8K Cr | ₹7.0K Cr | 21.0% | ₹4.2K Cr | ₹15.69 |
| 2019-03-31 | ₹29.1K Cr | ₹6.4K Cr | 22.0% | ₹3.2K Cr | ₹11.11 |
| 2018-03-31 | ₹26.5K Cr | ₹5.6K Cr | 21.0% | ₹2.5K Cr | ₹8.73 |
| 2017-03-31 | ₹31.6K Cr | ₹10.1K Cr | 32.0% | ₹7.8K Cr | ₹29.03 |
| 2016-03-31 | ₹28.5K Cr | ₹8.2K Cr | 29.0% | ₹5.7K Cr | ₹18.89 |
| 2015-03-31 | ₹27.4K Cr | ₹7.9K Cr | 29.0% | ₹5.5K Cr | ₹21.92 |
| 2014-03-31 | ₹16.1K Cr | ₹7.0K Cr | 44.0% | ₹3.9K Cr | ₹15.17 |
Compounded Growth Rates
Sales Growth
Profit Growth
EPS Growth
Peer Comparison
Pharma| Stock | Price | Fair Value | MoS% | P/E | ROE | Signal |
|---|---|---|---|---|---|---|
Par Drugs And Chemicals Limited | ₹86 | ₹469.7 | +81.7% | 7.3 | 15.4% | FAIRLY_VALUED |
IOL Chemicals and Pharmaceuticals Limited | ₹79.5 | ₹237.8 | +66.6% | 19.6 | 5.2% | FAIRLY_VALUED |
Kilitch Drugs (India) Limited | ₹132.7 | ₹321 | +58.7% | 17.7 | 9.4% | UNDERVALUED |
Bal Pharma Limited | ₹69 | ₹147.5 | +53.2% | 12.8 | 12.6% | FAIRLY_VALUED |
Zydus Lifesciences | ₹868 | ₹1,502.2 | +42.2% | 17.6 | 19.9% | UNDERVALUED |
Natco Pharma | ₹1,030 | ₹1,597 | +35.5% | 11.8 | 18.0% | UNDERVALUED |
Jagsonpal Pharmaceuticals Limited | ₹190.6 | ₹275.2 | +30.7% | 30.8 | 20.1% | UNDERVALUED |
Lupin | ₹2,280 | ₹3,112 | +26.7% | 22.4 | 23.8% | UNDERVALUED |
Institutional Activity
Bulk deals, block deals, short selling & delivery volume — NSE data
Insider Trading
Community Pulse
Company Documents
Annual reports, concall transcripts & regulatory filings
Share this Stock
Download card · Share on WhatsApp
Share on WhatsApp, Twitter, or any group — each share brings new users to Veritas Quant